将古巴生物技术研究应用于 COVID-19：全员上阵。

Bringing Cuban Biotech Research to Bear on COVID-19:All Hands and Minds on Deck.

出版信息

MEDICC Rev. 2020 Apr;22(2):31-37. doi: 10.37757/MR2020.V22.N2.9.

DOI:10.37757/MR2020.V22.N2.9

Abstract

This MEDICC Review roundtable gathers some of Cuba's top researchers in the fi elds of vaccines and biotechnology, all of whom work in institutions belonging to BioCubaFarma, the umbrella company of Cuban biotech and pharmaceutical R&D, production, distribution and export. Founded in 2012, the company is comprised of 34 enterprises with 61 lines of production and some 20,000 employees. A total of 765 of its products are registered in 53 countries and exported to an-other 50. Its scientists' research has resulted in 2640 patents in Cuba and globally.

摘要

本次《MEDICC 评论》圆桌会议聚集了古巴疫苗和生物技术领域的一些顶尖研究人员，他们均就职于古巴生物技术和制药研发、生产、分销和出口的伞式公司——BioCubaFarma 旗下的机构。该公司成立于 2012 年，由 34 家企业组成，拥有 61 条生产线，员工约 2 万人。其产品共有 765 种在 53 个国家注册，并出口到另外 50 个国家。该公司的科学家已在古巴和全球范围内获得了 2640 项专利。